Actively Recruiting
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Led by Hebei Medical University Fourth Hospital · Updated on 2024-06-17
58
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.
CONDITIONS
Official Title
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation and signed informed consent
- Age 18 to 75 years, any gender
- Confirmed limited-stage small cell lung cancer without distant metastasis
- Immunohistochemical results available
- Chemotherapy includes cisplatin or carboplatin combined with etoposide
- ECOG performance status of 0 or 1
- Weight over 40 kg
- Expected survival of at least 6 months
- At least one measurable lesion suitable for repeated assessment by CT or MRI
- No previous immunotherapy
- Adequate blood counts, liver, kidney, heart, lung function, and coagulation within specified limits
- Female participants must be postmenopausal or have a negative pregnancy test if premenopausal
You will not qualify if you...
- Distant organ metastases excluding supraclavicular lymph nodes
- Prior chest radiotherapy
- Contraindications to etoposide-platinum chemotherapy
- Active or history of autoimmune disease or recent immunosuppressive drug use
- Prior or current PD-1/PD-L1 immunotherapy or participation in other interventional studies
- Recent anti-tumor or long-term systemic immunotherapy or hormone therapy within 4 weeks
- Uncontrolled cardiac conditions including heart failure, unstable angina, recent myocardial infarction, or significant arrhythmias
- Immune deficiencies such as HIV, active hepatitis B or C, or active tuberculosis
- Active infection or unexplained fever over 38.5°C within 2 weeks before screening
- Other serious illnesses or conditions that may interfere with study participation or safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050011
Actively Recruiting
Research Team
W
Wenbin Shen, PhD
CONTACT
H
Hesong Wang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here